In the highly regulated and extremely competitive US Oncology market, it is critical that pharma and biotech players understand the investment and staffing levels needed for success today in key activities and functions before, during, and after the launch of a new oncology product.
Best Practices, LLC has conducted exclusive research and analysis to examine oncology product investment levels for 12 companies and 20 U.S. oncology launches across pre-launch, launch and post-launch periods.
This white paper provides evidence-based benchmarks around investment, staffing and timing requirements to effectively launch new oncology drugs in the U.S. market.